Gilead (GILD) Stock Could Be 50% Undervalued On New Oncology Trial News

Gilead Sciences has delivered a powerful run over the past few years. With the stock now around US$158, the key issue for investors is whether that climb is still in line with the cash the business can generate. Recent partnerships, acquisitions and legal settlements all feed back into one thing that matters for valuation: the durability and timing of Gilead’s future cash flows. Over the past 5 years, Gilead Sciences has returned 188.9%. This puts a lot of weight on the question of how much...